Autopsy report · NCT00482105

Early Diagnosis of Melanoma Using Expression Profiling and Non-Invasive Sampling of Skin Cells

“Withdrawn per sponsor and Investigator”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 1 year 5 months before it stopped.
• 7 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

University of California, Davis

Sponsor type

University, hospital or other

Conditions

Melanoma

Interventions

EGIR Tape

Participants

7

Sites

1

Countries

United States

Trials that died the same way

• BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
  “Withdrawn by sponsor” (84% match in meaning)
• Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
  “Study withdrawn by Sponsor” (83% match in meaning)
• A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy
  “Study was withdrawn per sponsor decision” (82% match in meaning)
• An Exploratory Investigation to Assess Changes in Quality of Life for Individuals With Type 2 Diabetes After Taking a Meal-replacement Shake.
  “Sponsor withdrawn” (82% match in meaning)
• Navelbine, Taxol, Herceptin and Neupogen in Stage IV Breast Cancer: A Phase I - II Trial
  “Sponsor withdrew the study” (81% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.